Study of VIR-2482 in Healthy Volunteers

Vir Biotechnology, Inc.100 enrolled

Overview

This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

100

Conditions

Influenza A

Interventions

VIR-2482DRUG

VIR-2482 given by intramuscular injection

PlaceboDRUG

Sterile normal saline (0.9% NaCl) given by intramuscular injection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy Male or Female age 18 to \< 65 years * Body mass index (BMI) of 18.0 kg/m\^2 to 32.0kg/m\^2 Exclusion Criteria: * Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation * History of influenza-like illness or confirmed influenza infection within 3 months prior to randomization. * Fever-like illness within 5 days of randomization. * History or clinical evidence of conditions considered high risk for developing influenza-related complications.

Locations (1)

Investigative Site

Brisbane, Queensland, Australia